HK1130008A1 - Use of thymosin alpha 1 for the treatment of immunological diseases - Google Patents

Use of thymosin alpha 1 for the treatment of immunological diseases

Info

Publication number
HK1130008A1
HK1130008A1 HK09107686.5A HK09107686A HK1130008A1 HK 1130008 A1 HK1130008 A1 HK 1130008A1 HK 09107686 A HK09107686 A HK 09107686A HK 1130008 A1 HK1130008 A1 HK 1130008A1
Authority
HK
Hong Kong
Prior art keywords
treatment
immunological diseases
thymosin alpha
thymosin
alpha
Prior art date
Application number
HK09107686.5A
Other languages
English (en)
Inventor
Luigina Romani
Francesco Bistoni
Enrico Garaci
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of HK1130008A1 publication Critical patent/HK1130008A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK09107686.5A 2006-05-19 2009-08-21 Use of thymosin alpha 1 for the treatment of immunological diseases HK1130008A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06010441 2006-05-19
PCT/EP2007/053321 WO2007134908A2 (en) 2006-05-19 2007-04-04 Use of thymosin alpha 1 for the treatment of immunological diseases

Publications (1)

Publication Number Publication Date
HK1130008A1 true HK1130008A1 (en) 2009-12-18

Family

ID=37498900

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09107686.5A HK1130008A1 (en) 2006-05-19 2009-08-21 Use of thymosin alpha 1 for the treatment of immunological diseases

Country Status (12)

Country Link
US (1) US8022036B2 (ko)
EP (1) EP2018180B1 (ko)
JP (2) JP2009537584A (ko)
KR (1) KR101488224B1 (ko)
CN (1) CN101448519B (ko)
AU (1) AU2007253527B2 (ko)
BR (1) BRPI0712595A2 (ko)
CA (1) CA2648889C (ko)
ES (1) ES2553267T3 (ko)
HK (1) HK1130008A1 (ko)
MX (1) MX2008014516A (ko)
WO (1) WO2007134908A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8716012B2 (en) * 2009-05-08 2014-05-06 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
CN103458681A (zh) * 2011-02-09 2013-12-18 赛生制药有限公司 用于预防感染、降低感染的严重性、及治疗感染的胸腺素α肽

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308833A (en) * 1992-02-06 1994-05-03 Sciclone Pharmaceuticals Method for treating hepatitis B carriers with minimal disease
WO1995012405A1 (en) * 1993-11-05 1995-05-11 Alpha 1 Biomedicals, Inc. Method and composition for treatment of patients having decompensated liver disease
US5750501A (en) * 1993-11-05 1998-05-12 Alpha 1 Biomedicals, Inc. Method and composition for treatment of patients having decompensated liver disease
DE19622422A1 (de) * 1996-06-04 1997-12-11 Sanorell Pharma Gmbh & Co Lagerungsstabile pharmazeutische Zusammensetzung mit immun - modulierenden und antiinflammatorischen Eigenschaften sowie ein Verfahren zu dessen Herstellung
WO1998035696A1 (en) * 1997-02-18 1998-08-20 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha 1 for the manufacture of a medicament for promoting stem cell development
US6197751B1 (en) * 1997-11-10 2001-03-06 The United States Of America As Represented By The Department Of Health And Human Services Thymosin α1 promotes tissue repair, angiogenesis and cell migration
CA2386346A1 (en) * 1999-09-30 2001-04-05 Curagen Corporation Novel polynucleotides and polypeptides encoded thereby
US20050058641A1 (en) * 2002-05-22 2005-03-17 Siemionow Maria Z. Tolerance induction and maintenance in hematopoietic stem cell allografts
NZ542900A (en) * 2003-03-28 2007-06-29 Sciclone Pharmaceuticals Inc Treatment of aspergillus infections with thymosin alpha 1
WO2005027958A1 (en) * 2003-09-19 2005-03-31 Imperial College Innovations Ltd Thymosin-beta-sulphoxide as an immunosuppressive active agent

Also Published As

Publication number Publication date
MX2008014516A (es) 2008-11-27
JP2014080441A (ja) 2014-05-08
US20090155260A1 (en) 2009-06-18
US8022036B2 (en) 2011-09-20
AU2007253527A1 (en) 2007-11-29
CN101448519A (zh) 2009-06-03
KR20090009963A (ko) 2009-01-23
ES2553267T3 (es) 2015-12-07
CN101448519B (zh) 2012-02-15
WO2007134908A3 (en) 2008-04-03
CA2648889C (en) 2016-02-23
KR101488224B1 (ko) 2015-02-04
JP5815767B2 (ja) 2015-11-17
JP2009537584A (ja) 2009-10-29
EP2018180A2 (en) 2009-01-28
BRPI0712595A2 (pt) 2012-07-03
CA2648889A1 (en) 2007-11-29
WO2007134908A2 (en) 2007-11-29
AU2007253527B2 (en) 2012-04-26
EP2018180B1 (en) 2015-08-26

Similar Documents

Publication Publication Date Title
EP1789034A4 (en) COMPOUNDS HAVING A DIPHENYL STRUCTURE FOR THE TREATMENT OF IMMUNE DISEASES
HK1171736A1 (en) Substituted acids for the treatment of respiratory diseases
ZA200707591B (en) Dihyrothienopyrimidines for the treatment of inflammatory diseases
PL2902026T3 (pl) Analogi tiazolidynodionu do leczenia choroby metabolicznej pośredniczonej przez zapalenie
EP2005168A4 (en) METHODS AND COMPOSITIONS FOR DIAGNOSING DISEASES OF AORTA
IL182643A0 (en) Novel composition and methods for the treatment of immune related diseases
EP1985302A4 (en) DRUGS FOR TUMOR THERAPY AND ITS USE
PL2056842T3 (pl) Modyfikowany galaktozyloceramid do leczenia chorób nowotworowych
IL178815A0 (en) The treatment of respiratory disease
HK1139861A1 (en) Pde7 inhibitors for use in the treatment of movement disorders 7(pde7)
EP2217238A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO PROTEINURIA
IL187274A0 (en) Use of docosahexaenoic glycerides for the treatment of tumoral diseases
IL196745A (en) Idabanon for use in providing mucosal pathways to treat disease
PT1945243E (pt) Utilização da calcitonina para o tratamento da ar
GB0410399D0 (en) The treatment of respiratory disease
EP1805210A4 (en) NOVEL PEPTIDES AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE
PL1890705T3 (pl) Zastosowanie 24-nor-UDCA do leczenia cholestatycznych chorób wątroby
HU0500145D0 (en) Composition for the treatment of oral diseases
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
EP2005964A4 (en) MEDICAMENT FOR TREATING HYPERPHOSPHATEEMIA AND PREPARATION METHOD THEREOF
HK1130008A1 (en) Use of thymosin alpha 1 for the treatment of immunological diseases
GB0415181D0 (en) Compounds for use in the treatment of infection
EP1865952A4 (en) COMPOSITIONS CONTAINING HISTAMINES FOR THE TREATMENT OF ALLERGIES
IL178907A0 (en) Use of sulglicotide for the treatment of mucositis
ZA200606780B (en) Compounds for the treatment of diseases

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170404